Table 6.
Summary statistics of data used in models reported in Table 7, by procurement type, 2010–2014
| Variables | Procurement Type | ||
|---|---|---|---|
| APPL (n = 593) |
National tender (n = 150) |
Direct Purchase (n = 522) |
|
| Number of medicines formulations, (%) | |||
| 2010 | 14.5 | 19.3 | 16.3 |
| 2011 | 27.5 | 23.3 | 18.2 |
| 2012 | 19.1 | 22.0 | 22.2 |
| 2013 | 17.7 | 18.0 | 21.5 |
| 2014 | 21.2 | 17.3 | 21.8 |
| Medicine source and category, (%) | |||
| Local generic | 70.2 | 32.0 | 36.4 |
| Imported generic | 20.2 | 18.0 | 30.3 |
| Originator | 9.6 | 50.0 | 33.3 |
| Route of administration, (%) | |||
| Injectables | 30.0 | 30.7 | 15.5 |
| Oral preparation | 61.5 | 60.6 | 62.8 |
| Other preparations | 8.5 | 8.7 | 21.7 |
| Median price ratioa (Interquartile range) | |||
| 2010 | 1.58 (0.92–3.03) | 2.08 (1.04–5.24) | 2.77 (1.59–5.64) |
| 2011 | 1.69 (0.98–5.89) | 1.98 (0.97–5.89) | 2.22 (1.41–5.00) |
| 2012 | 1.61 (0.84–3.81) | 1.24 (0.56–5.57) | 2.16 (1.26–4.65) |
| 2013 | 1.80 (0.83–3.84) | 1.52 (0.94–6.12) | 1.75 (1.14–4.08) |
| 2014 | 1.50 (0.81–3.98) | 1.35 (0.60–4.06) | 1.69 (1.11–4.19) |
| Total quantity (‘000,000 DDDs), Mean (SD) | 9.1 (33.5) | 3.9 (16.7) | 0.2 (0.6) |
| Total expenditure (‘000,000 MYR), Mean (SD) | 2.0 (5.4) | 1.6 (3.2) | 0.1 (0.3) |
a Unweighted 50th percentile price ratio relative to MSH international reference prices of all products by procurement type for each year